Notes
PMDA = Pharmaceuticals and Medical Devices Agency
Reference
Pharmaceuticals and Medical Devices Agency of Japan. Revisions of PRECAUTIONS (FY2019) - Mecasermin (genetical recombination); Atezolizumab (genetical recombination); Osimertinib mesilate; Bilastine. Internet Document : 3 Dec 2019. Available from: URL: http://www.pmda.go.jp/english/safety/info-services/drugs/revision-of-precautions/0007.html
Rights and permissions
About this article
Cite this article
Package insert revisions recommended by PMDA. Reactions Weekly 1783, 6 (2019). https://doi.org/10.1007/s40278-019-72489-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-019-72489-3